Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs

Left Atrial Systolic and Diastolic Dysfunction in Heart Failure with Normal Left Ventricular Ejection Fraction

“…63,64 In the current study using measurements at rest with two-dimensional speckle-tracking echocardiography, we have demonstrated that patients with HFNEF presented both systolic and diastolic LA dysfunction with subsequent reduced functional capacity during effort. Hence, we consider that in patients with HFNEF, treatments destined to improve LA systolic and diastolic function could be of great importance in the treatment of this complex disease for which, so far, no effective therapies exist.…”

The effects of spironolactone on atrial remodeling in patients with preserved left ventricular function after an acute myocardial infarction

“…There were limited studies available in the literature, which assessed the effects of aldosterone antagonists on atrial remodeling [1,[25][26][27]. First, an experimental heart failure model showed that spironolactone therapy improves LAEF and tends to prevent LA dilatation in dogs [25].…”

Emerging cardiovascular indications of mineralocorticoid receptor antagonists

“…Pre-treatment with spironolactone in a ventricular tachy-pacing AF model in dogs reduced the amount of atrial fibrosis and inducibility of AF [37]. Spironolactone also prevented AF-related changes in atrial structure and function in vivo in a canine model of persistent AF; reduced apoptotic cell death, myolysis, and mitochondrial swelling; and maintained left atrial ejection fraction [38].…”